School of Kinesiology and Health Studies, Queen's University
Kingston, Ontario, K7L 3N6, Canada
Location status: Recruiting
NCT Number: NCT05496751
In this proposal, the investigators challenge the assumption that following the physical activity guidelines implies benefit for ALL adults, and that if benefit is not achieved in response to first line therapy, it will be by simply exercising more. Thus, for improving cardiorespiratory fitness and cardiometabolic risk factors, unanswered questions include: 1) To what extent, regardless of increasing exercise intensity or amount, is exercise not associated with benefit? Demonstration of a resistance to benefit through exercise in a substantial number of adults would be a novel and important finding, would counter the assumptions of many if not most health care practitioners, and could have immediate and direct application in all health care settings. 2) To what extent will non-responders to first line therapy (150 min/wk) be required to increase exercise intensity or amount to achieve benefit? 3) To what extent will failure to improve CRF segregate (be associate with) with cardiometabolic risk factors? The investigators propose that adults who remain exercise resistant for improvement in CRF and cardiometabolic risk despite increasing amount or intensity are at high risk of metabolic disease and consequently, are candidates for alternative treatment strategies.
Interested in participating?
Request Info25 year–65 year
All sexes
Interventional
Not applicable
Kingston, Ontario, K7L 3N6, Canada
Location status: Recruiting
The trial has two objectives:
Primary objective: After 16 weeks of first line therapy (150 min/wk of MPA), does increasing exercise intensity or amount for 16 weeks improve cardiorespiratory fitness (CRF, VO2peak) deferentially depending on the CRF response at 16 weeks.
Secondary objective: Determine whether common cardiometabolic risk factors segregate/cluster with respect to variation in CRF to first line therapy in adults, and, whether clinically meaningful improvements in cardiometabolic risk factors segregate with improvement in CRF.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will exercise under supervision. Exercise dose will vary by amount and intensity
Participants will exercise under supervision. Exercise dose will vary by amount and intensity
Participants will exercise under supervision. Exercise dose will vary by amount and intensity
Time frame: Measured at baseline and every 4 weeks for 32 weeks.
Cardiorespiratory fitness will be determined using direct (open circuit spirometry) measures of oxygen consumption (expressed in L/min) obtained during a maximal treadmill test.
Time frame: Measured at baseline, 16 and 32 weeks.
Fasting glucose (mmol/L)
Time frame: Measured at baseline, 16 and 32 weeks.]
Fasting LDL- and HDL-cholesterol (mmol/L)
Time frame: Measured at baseline, 16 and 32 weeks.]
fasting insulin (pmol/L)
Time frame: Measured at baseline, 16 and 32 weeks.
fasting triglycerides (mmol/L)
Time frame: Measured at baseline, 16 and 32 weeks
Total adiposity
Time frame: Measured at baseline, 16 and 32 weeks.
Visceral adiposity
Time frame: Measured at baseline 16 and 32 weeks.
Lean mass
Time frame: Measured at baseline, 16 and 32 weeks.
Subcutaneous adiposity
Time frame: Measured at baseline 16 and 32 weeks.
waist circumference
Time frame: Measured at baseline, 16 and 32 weeks.
Body weight
Contact information is provided by the study sponsor or research team.
Robert Ross, PhD
Other
Response Variability to Exercise in Adults
Acronym: REVISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06840873
Behavior, COVID-19
Tiapei, Taiwan
View Trial DetailsNCT06657976
Arterial Occlusive Diseases, Arteriosclerosis
Chicago, Illinois, United States
View Trial DetailsNCT07590700
Basal Ganglia Diseases, Behavior
Hatay, Antakya, Turkey (Türkiye)
View Trial DetailsNCT06337708
Behavior, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial Details